Mylan to pay $465 million over EpiPen Medicaid rebate dispute

(Reuters) - Mylan NV on Friday said it will pay $465 million to settle the question of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.